Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by Wedbush

Vigil Neuroscience (NASDAQ:VIGL)‘s stock had its “outperform” rating reiterated by Wedbush in a research note issued to investors on Friday, Benzinga reports. They currently have a $23.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 475.00% from the stock’s previous close.

Other research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Vigil Neuroscience in a report on Thursday, September 14th. JMP Securities started coverage on shares of Vigil Neuroscience in a report on Wednesday, October 18th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Mizuho cut their target price on shares of Vigil Neuroscience from $15.00 to $13.00 in a report on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.20.

Vigil Neuroscience Stock Performance

VIGL stock opened at $4.00 on Friday. The firm has a fifty day moving average price of $6.34 and a 200 day moving average price of $7.62. Vigil Neuroscience has a fifty-two week low of $3.85 and a fifty-two week high of $14.00. The firm has a market cap of $143.52 million, a PE ratio of -1.96 and a beta of 2.78.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VIGL. Citadel Advisors LLC lifted its position in shares of Vigil Neuroscience by 0.9% during the second quarter. Citadel Advisors LLC now owns 2,180,324 shares of the company’s stock worth $20,495,000 after purchasing an additional 18,528 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Vigil Neuroscience by 704.7% in the second quarter. BlackRock Inc. now owns 821,452 shares of the company’s stock valued at $7,722,000 after acquiring an additional 719,366 shares in the last quarter. Rock Springs Capital Management LP bought a new stake in shares of Vigil Neuroscience in the first quarter valued at about $3,318,000. Vanguard Group Inc. bought a new stake in shares of Vigil Neuroscience in the first quarter valued at about $2,708,000. Finally, Geode Capital Management LLC raised its holdings in shares of Vigil Neuroscience by 153.4% in the second quarter. Geode Capital Management LLC now owns 284,843 shares of the company’s stock valued at $2,678,000 after acquiring an additional 172,451 shares in the last quarter. 71.80% of the stock is owned by hedge funds and other institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.